Provided by Tiger Trade Technology Pte. Ltd.

Imunon, Inc.

1.45
-0.0600-3.97%
Pre-market: 1.42-0.0300-2.07%08:34 EDT
Volume:1.10M
Turnover:1.75M
Market Cap:8.14M
PE:-0.41
High:1.75
Open:1.65
Low:1.39
Close:1.51
52wk High:5.85
52wk Low:1.39
Shares:5.61M
Float Shares:5.32M
Volume Ratio:36.13
T/O Rate:20.72%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5719
EPS(LYR):-6.8265
ROE:-429.72%
ROA:-77.99%
PB:4.20
PE(LYR):-0.21

Loading ...

Imunon Schedules Q2 Results, Business Update Conference Call

Reuters
·
Aug 04

Imunon Inc Expected to Post a Loss of 93 Cents a Share - Earnings Preview

Reuters
·
Jul 31

Imunon Says Phase 3 Ovation 3 Ovarian Cancer Trial Enrollment Outpaces Plan

Reuters
·
Jul 30

Imunon - Imnn-001 Demonstrates Favorable Safety Profile with no Serious Immune-Related Adverse Events

THOMSON REUTERS
·
Jul 30

Imunon - Reports Enrollment Rate Exceeding Forecast in Ovation 3 Trial

THOMSON REUTERS
·
Jul 30

Imunon Reports Strong Enrollment Momentum in Phase 3 Ovation 3 Trial of Imnn-001 in Advanced Ovarian Cancer

THOMSON REUTERS
·
Jul 30

Imunon - Projects Enrollment Completion in Q2 2029 for Ovation 3 Trial

THOMSON REUTERS
·
Jul 30

Imunon Announces Press Release Available

Reuters
·
Jul 23

IMUNON to Present IMNN-001 Data at Inaugural AACR Conference on Drug Discovery and Development

GlobeNewswire
·
Jul 23

Imunon General Counsel Susan Eylward Disposes of 2,150 Common Shares Worth $3,830.44

Reuters
·
Jul 22

Imunon Says Ovarian Cancer Drug Trial Preliminary Results Show Deeper Antitumor Response

MT Newswires Live
·
Jul 21

Imunon announces new preliminary data from IMNN-001 trial

TIPRANKS
·
Jul 21

Imunon - Imnn-001 Under Evaluation in Phase 3 Ovation 3 Trial for Advanced Ovarian Cancer

THOMSON REUTERS
·
Jul 21

Imunon Reports Positive Phase 2 Mrd Clinical Data for Imnn-001, Demonstrating the Successful Overcoming of Historical Il-12 Safety Barriers in Frontline Ovarian Cancer

THOMSON REUTERS
·
Jul 21

Imunon - no Cytokine Release Syndrome or Serious Immune-related Adverse Events Observed with Imnn-001

THOMSON REUTERS
·
Jul 21

Imunon - Imnn-001 Demonstrates Lower Mrd Rate, Higher Ctdna Clearance, and Higher Ned Rate vs Control

THOMSON REUTERS
·
Jul 21

Imunon - Imnn-001 Shows Highly Favorable Safety and Tolerability Profile

THOMSON REUTERS
·
Jul 21

IMUNON Reports Positive Phase 2 MRD Clinical Data for IMNN-001, Demonstrating the Successful Overcoming of Historical IL-12 Safety Barriers in Frontline Ovarian Cancer

GlobeNewswire
·
Jul 21

Imunon Files Form 3 for CFO Joshua Blacher

Reuters
·
Jul 08

Imunon General Counsel Susan Eylward Disposes of 920 Common Shares Worth $1,729.6

Reuters
·
Jul 08